Stock Market & Financial Investment News

News Breaks November 13, 2012 06:31 EDT ARIA Foundation Medicine, ARIAD announce collaboration to study AP26113 Foundation Medicine and ARIAD announced a genomic profiling collaboration to study AP26113, ARIAD's investigational dual-inhibitor of ALK and EGFR in patients with non-small cell lung cancer and other cancers. Foundation Medicine will work with ARIAD to generate genomic profile information for patients enrolled in ARIAD's ongoing Phase 1/2 trial and these data will be matched with clinical observations to understand the activity and selectivity profile of AP26113. News For ARIA From The Last 14 Days Check below for free stories on ARIA the last two weeks. Sign up for a free trial to see the rest of the stories you've been missing. May 20, 2013 07:34 EDT ARIA UBS to host a conference Subscribe for More Information May 17, 2013 08:22 EDT ARIA ARIAD shares should be bought on weakness, says BMO Capital Subscribe for More Information May 16, 2013 07:29 EDT ARIA Leerink to host a bus tour Boston Biopharma Bus Tour travels throughout Boston on May 16-17. Sign up for a free trial to see the rest of the stories you've been missing.